Semprus BioSciences closes $18 million Series B round

December 13, 2010 by MassDevice staff

Semprus Biosciences Corp. closes an $18 million Series B funding round, which CEO David Lucchino says it will use to build out its management team and fund manfuacturing ramp-up for its nanotech catheter coating.

Semprus logo

Semprus BioSciences Corp. reeled in $18 million in Series B financing for its nanotech medical device coating.

Semprus CEO David Lucchino told MassDevice that the company will use the proceeds to build a team of "been there, done that" medical device executives and to scale up its manufacturing operations.

"Investor expectations with this round of funding are that we would gain regulatory and clinicial clarity, along with having an initial product in hand to start initial sales. We're looking at the next 24 months as being that window," Lucchino told us.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp